BRIEF-Gbt Plans To Seek Expanded Labeling For Oxbryta® For Sickle Cell Disease
June 08, 2020 at 16:27 PM EDT
* GBT ANNOUNCES PLANS TO SEEK EXPANDED LABELING FOR OXBRYTA® (VOXELOTOR) TO TREAT CHILDREN AGES 4 TO 11 YEARS WITH SICKLE CELL DISEASE